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1. BRIEF BACKGROUND 
 
1.1 Trial overview 
The optimal management for women with preterm prelabour rupture of membranes 
(PPROM) is not known. Delivery may be planned for soon after the woman presents with 
PPROM, or alternatively delivery may be delayed (expectant management) in order for the 
fetus to gain additional maturity and reduce the risk of neonatal morbidity. However, 
expectant management may also increase the risk of ascending infection in the mother and 
thus of neonatal sepsis in the infant. In the face of insufficient evidence both forms of 
treatment are currently utilised. In Australia and New Zealand the two treatments (immediate 
delivery and expectant management) are equally employed amongst obstetricians. 
(reference #1) 
 
PPROMT is a prospective, multicentre randomised controlled trial comparing early planned 
birth versus expectant management for PPROM.  The protocol for the trial was published in 
2006 (reference #2). The trial is registered with the International Standard Randomised 
Controlled Trial Register (ISRCTN44485060]. Funding is from the Australian National Health 
and Medical Research (Grant Numbers 358387 and 1009898) and the University of Sydney. 
Eligible women were centrally randomised by the coordinating centre to either immediate 
planned delivery or expectant management, stratified by participating centre. Endpoint 
assessment is blinded, although blinding for participants was not possible. 
 
1.2 Timeline for the trial 
 
28 May 2004              First participant recruited to the trial 
 
26 February 2010 Interim analysis performed by Data Monitoring Committee,  
   determination made that trial should continue 
 
30 June 2013   Final participant recruited 
 
July 2013    Expert adjudication of primary outcome commences 
 
23 August 2013   Final participant gives birth,  
 
December 2013          Final peripartum trial forms received (collection of 4 month postpartum 
data will continue into 2014)  
 
January 2014   Trial baseline and peripartum data entry expected to be finalised and 
birth outcomes dataset locked, treatment assignment to be unblinded 
to data analysts and other trial researchers.  
 
2014   Final 4 month follow-up data to be received 
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1.3 Aims 
The primary aim of the study was to conduct a randomised controlled trial to answer the 
clinical question:  In women with preterm prelabour ruptured membranes (PPROM) between 
340 weeks and 366 weeks gestation is planned early delivery compared with expectant 
management associated with less neonatal and maternal morbidity? 
 
A secondary aim, to be carried out for centres in Australia, New Zealand and the UK, was to 
perform a costing of the outcomes to establish the economic impact of planned early delivery 
compared with expectant management. The costing will determine the net impact of each 
intervention on hospital resources. 
 
1.4 Study Design   
This was an international multi-centre randomised controlled clinical trial. Once women 
consented to be involved in the trial, they were randomised via a central telephone 
randomisation service to one of two treatment groups, early planned birth or expectant 
management.  Randomisation was 1:1, in balanced variable blocks and stratified by centre. 
Although treatment group allocation was concealed prior to randomisation, this was 
necessarily an unblinded trial. Both participants and obstetric care providers were aware of 
the treatment allocation. However, adjudication of the primary outcome (neonatal sepsis) 
was blinded to treatment allocation. 
 
Importantly, some women allocated to expectant management went into spontaneous labour 
and birth quickly. On the other hand, some women allocated to immediate delivery (by 
labour induction or prelabour caesarean section) had the birth delayed due to insufficient 
availability of delivery room resources.  In the latter case, immediate delivery proceeded as 
soon as it was deemed safe. 
 
1.5 Eligibility criteria 
Pregnant women between 340 weeks and 366 weeks gestation with PPROM and a singleton 
pregnancy were eligible for inclusion in the trial. Women with PPROM before 34 weeks 
gestation were approached about entering the trial, but could not be consented and 
randomised before 340 weeks.  
 
Exclusion criteria included established labour and indications for immediate delivery (clinical 
evidence of chorioamnionitis, meconium staining, haemorrhage or other contraindication to 
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expectant management). The presence of Group B streptococcus (GBS) was specifically not 
to be considered as a contraindication to expectant management. 
 
After randomisation, participants were to be managed in other respects according to local 
practice and protocols. Participating hospitals were encouraged to collect vaginal swabs and 
other pathology results (i.e. white cell count, C-Reactive protein [CRP]) after ROM but this 
was not a requirement. 
 
1.6 Intervention 
Early planned delivery group: Those women randomised to early planned birth were to 
have delivery scheduled as close to randomisation as possible and preferably within 24 
hours of randomisation. The mode of birth was determined by usual obstetric indications. 
Antibiotics were to be continued in the intrapartum period. 
 
Expectant management group: In women randomised to expectant management birth was 
to occur after spontaneous labour, at term or when the attending clinician felt that birth was 
indicated according to usual care. 
 
Care of the women was otherwise managed according to usual practice by the obstetric 
team with care of the infant by the attending neonatologist. 
 
1.7 Data collection and follow up  
Trial data was collected using separate forms at each of the following time points: 
Trial Entry Form: recorded at randomisation, with maternal and pregnancy characteristics 
including date of PPROM and management 
Antenatal Form (randomisation until birth): investigations and services use 
Labour and Delivery Form: delivery management 
Postnatal Form: delivery outcomes (ie birthweight, Apgar score), maternal complications, 
breastfeeding, maternal discharge from hospital 
Neonatal Form: completed at delivery hospital and includes neonatal investigations, 
management, adverse events and separation from hospital. 
 
Additionally, any neonatal death following discharge was requested to be separately notified 
to the trial manager. 
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Four month questionnaires were posted out to participants in English speaking countries 
(Australia, New Zealand, United Kingdom) to assess maternal wellbeing, satisfaction with 
care, breast feeding duration and early infant development. 
 
1.8 Trial endpoints 
1.8.1 Primary outcome: neonatal sepsis 
The primary outcome is neonatal sepsis at any time prior to discharge home of the neonate. 
Neonatal sepsis can be based on either definite indications such as a positive culture 
(definite sepsis) or on clinical signs and laboratory evidence of infection resulting in 
treatment with antibiotics (probable sepsis). Both definite and probable sepsis will count as 
an occurrence of the primary outcome. The outcome is being adjudicated by two 
neonatologists from the coordinating centre (see Appendix 1 for list of information used in 
the adjudication). The null hypothesis assumes that there will be no difference in the rate of 
neonatal sepsis between the two randomised arms of the trial. 
 
Definite systemic neonatal infection (definite sepsis) is defined as the presence of clinical 
signs of infection and a positive culture of a known pathogen from blood or cerebrospinal 
fluid (CSF), where the baby was treated with antibiotics for 5 or more days (or died before 5 
days). For organisms of low virulence and/or high likelihood of skin contamination of the 
blood culture, such as coagulase negative staphylococcus, both a positive blood culture and 
an abnormal full blood count or abnormal C-Reactive Protein (CRP)  were required. 
 
Clinical signs of infection include respiratory distress (requiring ventilation, continuous 
positive airway pressure  or supplemental oxygen for more than one hour), apnea, lethargy, 
abnormal level of consciousness, circulatory compromise (including hypotension, poor 
perfusion, need for inotropic support or volume expansion) and/or temperature instability 
(temperature <36oC or ≥38 oC) 
 
An abnormal full blood count (FBC) count includes abnormal white cell count1 (white cell 
count [WCC]<5 x 109 /L or WCC>30 x 109 /L), low platelet count2 (platelets <100,000), low 
neutrophil count1 (neutrophils  <1.5 x 109 /L ) or raised immature to total neutrophil ratio1 (I:T 
ratio >0.2). A CRP > 10mg/L was considered abnormal3,4. 
 
Probable neonatal infection (probable sepsis) is defined as the presence of clinical signs 
where the baby was treated with antibiotics for 5 or more days together with one or more of: 
an abnormal FBC; abnormal CRP; positive Group B Streptococcal (GBS) antigen on bladder 
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tap urine, blood or CSF; elevated CSF white cell count 5 (CSF WCC>100 x106/L); growth of 
a known virulent pathogen (eg GBS, E.coli, Listeria) from surface swab; or a histologic 
diagnosis of pneumonia in an early neonatal death.      
 
1.8.2 Secondary infant outcomes 
1. Composite neonatal morbidity (sepsis, mechanical ventilation or death) will be analysed 
as a dichotomous outcome and includes infants with one or more of: 
 
Sepsis (the primary outcome), mechanical ventilation ≥24 hours (#6 below), or 
perinatal death (#2 below).  
 
The purpose of the composite outcome is to represent the competing risks (neonatal 
sepsis versus need for respiratory support) posed by expectant management versus 
immediate delivery. 
 
2. Perinatal death (stillbirth or neonatal death) will be analysed as a dichotomous outcome 
as obtained from: 
Yes in response to Question 9 of the trial Postnatal Form [‘yes’ or ‘no’ tick box for  
Perinatal death] or, 
“Died” as the response to Question 46.2 of the trial Neonatal Form [This question 
relates to the discharge status of live born infants has 3 options – discharged home, 
transferred hospital, or died] or,  
A neonatal death (death within the first 28 days of life) directly notified by the site 
coordinator. 
 
3. Respiratory distress syndrome will be analysed as a dichotomous outcome, as obtained 
from: 
Respiratory distress syndrome (RDS) in response to Question 6 of the trial Neonatal 
Form [nine tick box options, 6.2 is RDS]. 
 
4. Pneumonia will be analysed as a dichotomous outcome, as obtained from: 
Pneumonia in response to Question 6 of the trial Neonatal Form [nine tick box 
options, 6.4 is Pneumonia] 
 
5. Any mechanical ventilation will be analysed as a dichotomous variable as obtained from: 
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Yes in response to Question 7 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Mechanical ventilation including intermittent positive pressure ventilation (IPPV), 
continuous positive airway pressure (CPAP) and/or high frequency oscillatory 
ventilation (HFOV)]. 
 
6. Mechanical ventilation for twenty  four hours or more will be analysed as a dichotomous 
variable obtained from: 
Duration of the mechanical ventilation in days in response to Question 7.1 of the trial 
Neonatal Form [free text fields for duration of ventilation collected in days, or if less 
than 1 day, in hours]. 
 
7. Birthweight will be analysed as a continuous variable, as obtained from: 
Birthweight in the response to Question 6 in the “Infant Details” section of the trial 
Postnatal Form [free text field for birthweight in grams]. 
 
8. Small for gestational age (SGA) defined as <10th percentile birthweight for week of 
gestation, by gender, will be analysed as a dichotomous variable using an Australian 
standard for singletons (10th percentiles shown in Appendix 2), with the data obtained 
from: 
Birthweight in the response to Question 6 in the “Infant Details” section of the trial 
Postnatal Form [free text field for birthweight in grams], and  
Gestational age (GA) in completed weeks in the response to Question 1 in the “Infant 
Details” section of the trial Postnatal Form [free text field in weeks and days], and 
Baby sex in the response to Question 2 in the “Infant Details” section of the trial 
Postnatal Form.  
 
9. Apgar score <7 at 5 minutes will be analysed as a dichotomous variable, as obtained 
from: 
Apgar Scores at 5 minutes in response to Question 3 in the “Infant Details” section of 
the trial Postnatal Form [free text field for Apgar scores range from 0 to 10]. 
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10. Antibiotics in first 48 hours will be analysed as a dichotomous variable, as obtained 
from: 
Yes in response to Question 20 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Antibiotics administered in 1st 48 hours] 
 
11. Lumbar puncture will be analysed as a dichotomous variable, as obtained from: 
Yes in response to Question 15 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Lumbar puncture in 1st 48 hours after birth] and/or 
Yes in response to Question 28 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Lumbar puncture in >48 hours after birth] and/or 
Recording one or more investigations for Lumbar puncture in Question 45.9 of the 
trial Neonatal Form  
 
12. Circulatory compromise requiring arterial line, fluid bolus or inotropic support will be 
analysed as a dichotomous variable, as obtained from: 
Yes in response to Question 21 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Circulatory compromise in 1st 48 hours. Question 21.1 contains five tick box 
indications  ‘a’ being Arterial line inserted, ‘c’ being Fluid bolus/volume expansion,  
and ‘d’ being Ionotropic support, more than one indication can be ticked] and/or 
Yes in response to Question 32 of the trial Neonatal Form [‘yes’ or ‘no’ tick box for 
Circulatory compromise at time of 1st systemic infection >48 hours. Question 32.1 
contains five tick box indications  ‘a’ being Arterial line inserted, ‘c’ being Fluid 
bolus/volume expansion,  and ‘d’ being Ionotropic support, more than one indication 
can be ticked ]  
 
13. Total duration of stay in special care nursery (SCN) or intensive care unit (ICU) will be 
analysed as a continuous variable as obtained from:  
Total time in days spent in a SCN and/or ICU in response to Question 4.2 of the trial 
Neonatal Form [free text fields for duration of admission collected in days, or if less 
than 1 day, in hours]. 
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14. Duration of infant hospitalisation at the birth hospital for infants discharged alive will be 
analysed as a continuous variable, as obtained from: 
The difference between the date of birth [delivery date (day/month/year) from 
Question 3 of the labour and Delivery form] and date of transfer or discharge home 
[(day/month/year) in response to Question 46 of the trial Neonatal Form]. 
 
15. Infant receiving breast milk at discharge will be analysed as a dichotomous variable, as 
obtained from:  
Yes if infant receiving any breast milk based upon the response to Question 2 in the 
“Feeding” section of the trial Postnatal Form [tick box options for exclusive breast 
milk, partial breast milk, formula only or unknown at the time of maternal discharge]. 
 
 
1.8.3 Secondary maternal and pregnancy outcomes  
1. Antepartum haemorrhage will be analysed as a dichotomous variable, as obtained from: 
Yes in response to Question 9 of the trial Antenatal Form [ “yes’ or ‘no’ tick box for 
Antepartum Haemorrhage], and/or 
Yes in response to Question 12 of the trial Labour and Delivery Form [ “yes’ or ‘no’ 
tick box for Intrapartum bleeding]. 
 
2. Cord prolapse  will be analysed analysed as a dichotomous variable, as obtained from: 
Yes in response to Question 10 of the trial Antenatal Form [ ‘yes’ or ‘no’ tick box for 
Cord Prolapse] 
 
3. Cephalic presentation at birth will be analysed as a dichotomous variable, as obtained 
from: 
Cephalic presentation in response to Question 5 of the trial Labour and Delivery 
Form [tick box options of ‘cephalic’, breech’ or ‘other’]. 
 
4. Chorioamnionitis as delivery indication will be analysed as a dichotomous variable, as 
obtained from: 
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Yes if indicated on any of Question 7.2.e of the Labour and Delivery Form [ among 
women who have labour induced, Question 7.2 contains six tick box indications for 
induction ‘e’ being Chorioamnionitis, more than one indication can be ticked], or 
Yes if indicated on any of Question 8.2.e of the Labour and Delivery Form [ among 
women who have a caesarean section, Question 8.2 contains six tick box indications 
for induction ‘i’ being Chorioamnionitis, more than one indication can be ticked] 
 
Chorioamnionitis as a finding from placental histology will be not be used. Placental 
histology was not uniformly requested. Obstetric teams were not blinded to treatment 
assignment and may have differentially requested placental histology based upon 
awareness of allocation to expectant management or not.  
 
5. Intrapartum fever will be analysed as a dichotomous variable, as obtained from: 
Yes in response to Question 13 of the trial Labour and Delivery Form [‘yes’ or ‘no’ 
tick box for Pyrexia above or equal to 38.5 degrees Celsius]. 
 
6. Postpartum antibiotics will be analysed as a dichotomous variable, as obtained from: 
Yes response to Question 5 in the “Postnatal Maternal Complications” section of the 
trial Postnatal Form [‘yes’ or ‘no’ tick box for Antibiotics postpartum]. 
 
7. Postpartum haemorrhage will be analysed as a dichotomous variable, as obtained from: 
Defined as blood loss ≥1000 ml in response to Question 17 of the trial Labour and 
Delivery Form [blood loss records in millilitre]. 
 
8. Thromboembolism  (which can include superficial thrombophlebitis) will be analysed as a 
dichotomous variable, as obtained from: 
Yes response to Question 11 of the trial Antenatal Form [ ‘yes’ or ‘no’ tick box for 
Thrombosis/Thromboembolism requiring treatment], and/or 
Yes in response to Question 4 in the “Postnatal Maternal Complications” section of 
the trial Postnatal Form [‘yes’ or ‘no’ tick box for Deep Vein Thrombosis 
(DVT)/Thromboembolism]. 
 
9. Maternal length of hospitalisation at the birth hospital will be analysed as a continuous 
variable, as obtained from: 
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Days in hospital from randomisation to delivery response to Question 24 of the trial 
Antenatal Form [free text fields for duration of hospitalisation(s) collected in days], 
plus 
The difference between the date of birth [delivery date (day/month/year) from 
Question 3 of the labour and Delivery form] and date of transfer or discharge home 
[(day/month/year) in response to Question 6 in the “Mother’s Separation from 
Delivery Hospital” section of the trial Postnatal Form]. 
 
 
Time until delivery, onset of labour and mode of delivery 
Time from randomisation until delivery should be directly related to treatment allocation. The 
onset of labour and mode of delivery will also be directly related, as planned immediate 
delivery would require either induction or a prelabour caesarean, unless labour commences 
spontaneously prior to a planned birth. Time until delivery, labour onset and mode of delivery 
are not trial endpoints, but are important results. Time until delivery, by treatment allocation 
and week of randomisation, will be reported as shown in dummy Table 2. Onset of labour 
and subsequent mode of delivery  by treatment allocation will be reported as shown in 
dummy Table 3. The percentage of “expectant management” women who delivered within 
48 hours of randomisation, and the number of women in “immediate delivery” who delivered 
at or more than 48 hours after randomisation will be reported in the trial text, as an indication 
of how well treatment allocation and actual treatment were aligned. 
 
2. STATISTICAL ANALYSIS 
2.1 Study size 
The study sample size, as described in the trial protocol, was set at 1812 women so as to 
have 80% power to detect a statistically significant difference if the population sepsis rate 
was 5.0% in one arm and 2.5% in the other arm. The significance level was set at a two-
tailed P<0.05, even though a reduced sepsis rate in the expectant management group was 
considered improbable. 
 
2.2 Participant flow diagram 
A CONSORT (Consolidated Standards of Reporting Trials) type diagram will be used to 
show the flow of participants into the final analysis. This is expected to be Figure 1. Only 
participants for whom the primary outcome is available will be included in the final analyses. 
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2.3 Analysis Principles 
All analyses will be by intention-to-treat. The number of participants lost to follow-up will be 
reported. No participants will be excluded from the primary intention to treat analysis due to 
protocol violations.  There will be no per-protocol analyses. Analyses will conform with 
guidelines promulgated by Consolidated Standards of Reporting Trials (CONSORT) 
(reference # 3) 
 
Preliminary descriptive analyses of the frequency of randomisation and pre-randomisation 
characteristics using blinded trial data (does not include a treatment assignment field) will be 
performed. Analyses of trial outcomes will not be performed until the statistics plan is 
finalised. 
 
2.3.1 Distribution of baseline variables 
Maternal and pregnancy characteristics at or before randomisation, by trial arm, will be 
shown in Table 1 (see dummy table, page 17). Additional information, such as participants 
by country/region will be included in the Results text of the trial report. 
 
2.3.2 Missing baseline variables 
There will be no imputation for missing values, with one exception: women who are missing 
either time of randomisation (24 hour clock) or time of PPROM, but not missing day of 
randomisation or day of PPROM. For these women, the hours from PPROM to 
randomisation will be calculated as the difference in days between randomisation and 
PPROM (multiplied by 24)  plus an imputed nine hours (four, five and six hours were the 
mode values for non-missing participants randomised within 24 hours, nine hours was the 
median). 
 
2.3.3 Missing primary outcome 
Only participants for whom the primary outcome is available will be included in the final 
analyses. Thus there will be no imputation for missing values of the primary outcome. 
 
2.3.4 Unadjusted analysis of primary outcome 
Event numbers and percentages will be reported, by treatment arm as in dummy Table 4. 
Statistical significance will be two-sided at the P<0.05 level. Effect measures (relative risk) 
will be reported with a 95% confidence interval.  
 
2.3.5 Adjusted analysis of primary outcome 
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A decision as to whether to perform adjusted analyses will NOT be determined by statistical 
testing of baseline differences between treatment arms, consistent with CONSORT 
recommendations (CONSORT Additional analyses, Item 12b). The randomisation process 
will be assessed by comparing the trial arms for clinically meaningful differences in the two 
important factors (at time of randomisation) in relation to potential neonatal sepsis and 
morbidity: 1) duration from PROM to randomisation  2)  gestational age at randomisation.  
Criterion 1 will be triggered if there is a relative difference (the difference in median duration, 
divided by the larger of the two duration times) of >15% between trial arms in the median 
hours from PPROM to randomisation. As an example, a median of 22 hours in one arm and 
26 hours in the other would meet this criterion. Criterion 2 is if the median gestational age at 
randomisation differs by > 3 days between arms. If either of these two conditions is met, 
then adjusted analyses will be required.  
If adjusted analyses is required per the above, a logistic regression model will be used. The 
covariates initially included as potential confounders will be: maternal age category (<20, 20-
24, 25-29, 30-34, ≥35), parity category (0, 1, ≥2), gestational week at PPROM, hours from 
PPROM to randomisation ( <4, 4 to <24, 24 to <48, ≥48), any pregnancy hypertension 
(yes/no), gestational diabetes,  antenatal urinary tract infection, positive culture for GBS at or 
before randomisation (yes/no), any other positive culture for abnormal vaginal flora at 
PPROM (yes/no), and treatment with antibiotics at randomisation or preceding 24 hours 
(yes/no). Backwards elimination will be used for factors which do not meet a statistical 
significance level of P=0.50, or alternatively to maintain a minimum events:covariates ratio of 
10:1n the model. Results will be reported as RR and 95% CI, as estimated from the model 
odds ratio and 95% CI. 
 
2.3.6 Missing secondary outcomes 
There will be no imputation for missing values.  
 
2.3.7 Analysis of secondary outcomes 
Event numbers and percentages will be reported, by treatment arm. Dichotomous primary 
and secondary outcomes will be compared between treatment arms by calculating relative 
risks and 95% confidence intervals (RR, 95% CI), using expectant management as the 
comparison group. No adjustment to the level of statistical significance will be made for 
multiple comparisons. Comparison of mean birthweight will be performed using a t-test. 
Comparisons of maternal and infant length of stay (days) will be performed using non-
parametric Mann-Wilcoxon tests. 
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If an adjusted analysis of the primary outcomes is required (per the “adjusted analysis of 
primary outcome” section above), there will also be similar adjusted analyses for secondary 
outcomes. 
 
2.3.8 A priori subgroup analyses 
The only pre-specified subgroup analyses will be for the primary outcome of neonatal sepsis 
and are shown in dummy Table 5: baseline subgroups by time from PPROM until 
randomisation, gestational week of PPROM, vaginal swab culture result and antibiotic 
administration at randomisation. 
 
2.3.9 Post-hoc hypotheses generating subgroup analyses 
Any post-hoc analyses (analyses not pre-specified in this SAP) which are completed to 
support the planned analyses will be clearly identified as such in any reporting of the trial.
Statistical Analysis Plan_Final  December 
 2013   Page 18 of 26 
 
3. DUMMY TABLES 
Table 1  Maternal and pregnancy factors at or before time of randomisation 
 
 Early planned 
birth 
n (%) 
Expectant 
management 
n (%) 
Rupture of membranes   
   <280 weeks   
   280 to 296 weeks   
   300 to 316 weeks   
   320 to 336 weeks   
   340 to 346 weeks   
   350 to 356 weeks   
   360 to 366 weeks   
Randomised   
   340 to 346 weeks   
   350 to 356 weeks   
   360 to 366 weeks   
PPROM ≥ 48 hours before randomisation   
   
Maternal age (years) (mean, std.dev.)   
Previous pregnancies   
   0   
   1   
   ≥ 2   
Cephalic presentation   
Previous caesarean section   
Previous PPROM or preterm delivery   
Previous stillbirth or neonatal death   
Pregnancy hypertension (onset ≥ 20 weeks)   
Gestational diabetes   
Antenatal urinary tract infection   
Antibiotics given†   
   intravenous (+/- oral)   
   oral only   
Steroids given   
Positive culture from a vaginal swab††   
   any positive culture   
   Group B streptococcus positive   
†   antibiotics at randomisation or in preceding 48 hours 
††   culture resulting from vaginal swab after PPROM and at or before randomisation 
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Table 2  Time from randomisation until birth, by treatment assignment 
 
Week 
randomised 
Immediate delivery 
days until birth 
median (10th- 90th centiles) 
Expectant management 
days until birth 
median (10th-90th centiles) 
34   
35   
36   
 
 
 
 
 
 
Table 3  Onset of labour and delivery mode, by treatment assignment 
 
Onset of labour and delivery 
mode 
Immediate delivery 
n (%) 
Expectant management 
n (%) 
Spontaneous labour   
  Vaginal birth   
  Caesarean section   
   
Labour induction   
  Vaginal birth   
  Caesarean section   
   
Pre-labour caesarean section   
   
Total caesarean sections   
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Table 4   Infant and maternal outcomes by treatment assignment 
 
Infant outcome Immediate 
delivery 
n (%) 
Expectant 
management 
n (%) 
Relative risk 
RR (95% CI) 
Neonatal sepsis    
    
Secondary infant outcomes    
Composite of neonatal morbidity (sepsis, 
ventilation ≥24 hours or death) 
   
Perinatal death    
Respiratory distress syndrome    
Pneumonia    
Any mechanical ventilation    
  mechanical ventilation for ≥ 24 hours    
Birthweight (grams; mean and std. dev.)    
SGA <10th percentile size    
Apgar score <7 at 5 minutes    
Antibiotics in first 48 hours    
Lumbar puncture    
Circulatory compromise    
Infant days in hospital*    
Days in SCN/NICU†*    
Receiving breast milk at discharge    
    
Secondary maternal and pregnancy outcomes 
Antepartum haemorrhage    
Cord prolapse    
Chorioamnionitis as delivery indication    
Intrapartum fever    
Postpartum antibiotics    
Postpartum haemorrhage    
Maternal duration of hospitalisation*    
*  median and interquartile range reported for duration of admission, Wilcoxon P value for test of null hypothesis 
of no difference in distribution between treatment arms 
†  days in a Special Care Nursery and/or Neonatal Intensive Care Unit 
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Table 5: Pre-specified subgroup analyses for neonatal sepsis 
Infant outcome Immediate 
delivery 
Sepsis 
n/N (%) 
Expectant 
management 
Sepsis 
n/N (%) 
Neonatal 
sepsis 
RR (95% CI) 
Duration from PPROM to randomisation     
  < 48 hours    
  ≥ 48 hours    
    
Gestation of PPROM    
  before 34 weeks    
  ≥ 34 weeks    
    
Positive vaginal culture after PPROM†    
  GBS     
  other organism    
  normal  flora or no culture collected    
    
Maternal antibiotics at randomisation††    
  Yes     
  No    
    
Cephalic presentation at randomisation    
  Yes    
  No    
†   culture resulting from vaginal swab after PPROM and at or before randomisation 
††  antibiotics at randomisation or in preceding 48 hours 
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4. ADDITIONAL ANALYSES 
4.1 Costing Analysis 
The costing analysis will be limited to participants from hospitals in Australia, New Zealand 
and the UK depending upon availability of cost information. 
 
The costing component will be conducted in accordance with the methods outlined in 
Drummond et al 1997 and will adopt a health system approach (reference #4). Costs will be 
based on direct health care costs for mothers and babies and the cost of additional 
resources associated with interventions of the study; and determined for women and their 
infants in each treatment group. Maternal health service utilisation will be estimated from the 
time of recruitment and all subsequent maternal and infant hospitalisations, length of stay 
and resource use applied up to discharge home from the birth admission. A further analysis 
will include costs up to four months postpartum for subgroup of women for whom this 
information is available.  
 
Costing for each maternal and infant hospitalisation will be determined using the Australian 
Refined Diagnosis Related Groups (AR-DRG) classification code assigned for each episode 
of care (hospitalisation). This code is developed by the Commonwealth Department of 
Health and Ageing and is based on clinical diagnosis and procedures and their associated 
costs of treatment and resource consumption for each episode of acute inpatient care. 
Maternal AR-DRG are calculated and based on maternal medical conditions, mode of 
delivery and obstetric complications, while neonatal AR-DRG are categorised by birth 
weight, with or without significant operating procedures or major problems.  Average per 
diem costs will be applied to each AR-DRG. Cumulative number of hospital in-patient days 
will be calculated by aggregating the length of stay of each relevant admission. 
 
Additional micro-costing of health care resource use will be conducted as these may be 
related to treatment allocation in the trial and prescribed in addition to routine clinical care. 
Further, many tests and procedures may not require hospitalisation or only outpatient care 
and thus, would not be recorded as an episode of care or assigned an AR-DRG. For 
mothers, diagnostic procedures and testing that may be carried out include blood tests, 
vaginal swabs and cultures, CTG monitoring, ultrasound and use of medications and 
antibiotics. For babies, additional procedures such as oxygen therapy, resuscitation, blood 
tests, blood and urine cultures, lumbar puncture, chest x-rays, ultrasounds and use of 
medications may be required for investigation and treatment. These will then be costed by 
Statistical Analysis Plan_Final  December 
 2013   Page 23 of 26 
 
aggregating the corresponding scheduled unit cost assigned by the Medicare Benefits 
Schedule or Pharmaceutical Benefits Schedule. 
 
All of the results will be analysed according to the intention to treat approach. The number of 
episodes of care and resource utilisation and associated costs over the trial period will be 
quantified and aggregated for mothers and infants in each arm of the trial. Average cost 
analysis will be conducted whereby the mean rate of hospitalisations and use of resources 
will be calculated and compared between groups using t-tests or the distribution-free 
equivalent, as required.  The distribution of costs data is commonly skewed so bootstrap re-
sampling will be used to estimate standard error and 95% confidence intervals. (reference 
#5) Sensitivity analyses will be explore any uncertainty of costs. 
 
4.2 Four month postpartum follow-up 
Trial data collected also includes an SF36 Health Survey questionnaire sent out at four 
months postpartum, on maternal satisfaction with care and wellbeing. Data collection for this 
part of the study was ongoing as of the end of 2013. The results of the questionnaire will be 
analysed and reported separately from the main trial analysis. Participants in the trial were 
necessarily aware of their treatment assignment, so their self-reported outcomes on the 
SF36 were not blinded. A separate analysis plan will be prepared for the 4 month 
follow-up, prior to commencing that analysis. 
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APPENDIX 1 
 
PPROMT SEPSIS ADJUDICATION 
Sepsis definitions: modified from trial protocol published in BMC Pregnancy 
and Childbirth with additions (noted in italics) and some minor alterations/exclusions due 
to lack of data alterations (see comments).  
prepared by Dr. Jennifer Bowen, Department of Neonatology, Royal North Shore Hospital 
 
Definite systemic neonatal infection was defined as the presence of clinical signs of 
infection and a positive culture of a known pathogen from blood or cerebrospinal fluid, where 
the baby was treated with antibiotics for 5 or more days (or died before 5 days). For 
organisms of low virulence and/or high likelihood of skin contamination of the blood culture, 
such as coagulase negative staphylococcus, both a positive blood culture and an abnormal 
full blood count or abnormal C-Reactive Protein (CRP)  were required. 
Clinical signs of infection include respiratory distress (requiring ventilation, continuous 
positive airway pressure  or supplemental oxygen for more than one hour), apnoea, lethargy, 
abnormal level of consciousness, circulatory compromise (including hypotension, poor 
perfusion, need for inotropic support or volume expansion) and/or temperature instability 
(temperature <36oC or ≥38 oC). Poor feeding was not included as a clinical sign of infection, 
as IG tubes may be required due to prematurity alone. 
An abnormal FBC count includes abnormal white cell count1 (wcc <5 x 109 /L or wcc >30 x 
109 /L), low platelet count2 (platelets <100,000), low neutrophil count1 (neutrophils  <1.5 x 109 
/L ) or raised immature to total neutrophil ratio1 (I:T ratio >0.2). A CRP > 10mg/L was 
considered abnormal3,4. 
Raised immature neutrophil count was not included as a sign of clinical infection, as it is not 
useful alone. Information on degenerative morphological changes to neutrophils  (toxic 
granulation or vacuolization) was not available from the trial data. 
Probable neonatal infection was defined as the presence of clinical signs where the baby 
was treated with antibiotics for 5 or more days together with one or more of: an abnormal 
FBC; abnormal CRP; positive Group B Streptococcal (GBS) antigen on bladder tap urine, 
blood or CSF; elevated CSF white cell count 5 (CSF wcc >100 x106/L); growth of a known 
virulent pathogen (eg GBS, E.coli, Listeria) from surface swab; or a histologic diagnosis of 
pneumonia in an early neonatal death.      
 References:  
1. Ottolini MC, Lundgren K, Mirkinson LJ, Cason S and Ottolini MG. Utility of complete 
blood count and blood culture screening to diagnose neonatal sepsis in the 
asymptomatic at risk newborn. Pediatr Infect Dis J 2003;22:430-4 
2. Guida JD, Kunig AM, Leef KH, McKenzie SE and Paul DA. Platelet count and sepsis 
in very low birth weight neonates: is there an organism specific response? Pediatrics 
2003;111:1411-15 
3. Philip AGS and Hewitt JR. Early diagnosis of neonatal sepsis. Pediatrics 
1980;65:1036-4 
4. Philip AGS, Mills PC. Use of C-reactive protein in minimising antibiotic exposure: 
experience with infants initially admitted to a well-baby nursery. Pediatrics 
2000;106:e4  
5. Isaacs D, on behalf of the Australasian Study Group for Neonatal Infections. A ten 
year, multicentre study of coagulase negative staphylococcal infections in 
Australasian neonatal units 
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APPENDIX 2 – 10th birthweight percentile cut-points by gestational age and 
gender (from Dobbins et al. Australian national birthweight percentiles by sex and 
gestational age, 1998-2007. MJA. 2012 Sep 3;197(5):291–4) 
 
 
Gestation Males Females 
(weeks)   
34 1860 1764 
35 2080 1980 
36 2295 2198 
37 2540 2430 
38 2800 2690 
39 2950 2830 
40 3090 2975 
41 3220 3090 
42 3250 3110 
43 3085 3010 
44 3110 3070 
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